Business
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with Sanofi - - Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer - - Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 - - New report
About this update from Sanofi Sa
[{"type":"image","alt":"Immuneering Corporation","displaySize":"","headline":null,"caption":"Immuneering Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":74,"url":"https://media.zenfs.com/en/globenewswire.com/d79b6ec93b1d4423e8a0934e6a765313"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fGFUZ0nWiGak7K0u9vVc2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d79b6ec93b1d4423e8a0934e6a765313","width":300,"height":74}},"lazy":false},{"type":"text","content":"- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP -","length":134,"tagName":"p"},{"type":"text","content":"- Raised $225 million of financing, including $25 million private placement with Sanofi -","length":89,"tagName":"p"},{"type":"text","content":"- Cash runway extended into 2029, including through topline readout of planned Phase 3 trial of atebimetinib + mGnP in first-line pancreatic cancer -","length":149,"tagName":"p"},{"type":"text","content":"- Granted U.S. composition of matter patent for atebimetinib that is expected to provide exclusivity into 2042 -","length":112,"tagName":"p"},{"type":"text","content":"- New reports of first-line pancreatic cancer patients with excellent responses to atebimetinib + FOLFIRINOX, including a patient with a complete response and a responding patient who was able to advance to radiation and surgery with curative intent -","length":251,"tagName":"p"},{"type":"text","content":"- Conference call scheduled for today, November 12, 2025, at 4:30 pm ET -","length":73,"tagName":"p"},{"type":"text","content":"NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the third quarter ended September 30, 2025, and provided business and clinical updates.","length":312,"tagName":"p"},{"type":"text","content":""The third quarter was truly transformational for Immuneering. We announced extraordinary overall survival data from our ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer and raised $225 million of cumulative financing on the strength ...